Erratum to: A Stable Human-Cell System Overexpressing Cystic Fibrosis Transmembrane Conductance Regulator Recombinant Protein at the Cell Surface [Mol Biotechnol, DOI 10.1007/s12033-014-9830-5];A Stable Human-Cell System Overexpressing Cystic Fibrosis Transmembrane Conductance Regulator Recombinant Protein at the Cell Surface

Molecular Biotechnology

Volumn 57, Issue 5, 2015, Pages 391-405

  Hildebrandt, Ellen ^a   Ding, Haitao ^b   Mulky, Alok ^b   Dai, Qun ^b   Aleksandrov, Andrei A ^c   Bajrami, Bekim ^d   Diego, Pamela Ann ^d   Wu, Xing ^b   Ray, Marjorie ^e   Naren, Anjaparavanda P ^f   Riordan, John R ^c   Yao, Xudong ^d   DeLucas, Lawrence J ^e   Urbatsch, Ina L ^a   Kappes, John C ^b,g,h,i  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g University of Alabama at Birmingham   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Biophysical analysis; CFTR; HEK293; Mammalian cell; Overexpression

Indexed keywords

BIOLOGICAL MEMBRANES; BIOPHYSICS; CELL MEMBRANES; CHLORINE COMPOUNDS; CYTOLOGY; FLUORESCENCE; MAMMALS; MASS SPECTROMETRY; PURIFICATION; SIZE EXCLUSION CHROMATOGRAPHY;

BIOPHYSICAL ANALYSIS; CFTR; HEK-293; MAMMALIAN CELLS; OVER-EXPRESSION;

RECOMBINANT PROTEINS;

CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HYBRID PROTEIN;

BIOTECHNOLOGY; CELL CULTURE; CELL MEMBRANE; GENE EXPRESSION; GENETICS; GLYCOSYLATION; HEK293 CELL LINE; HUMAN; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; METABOLISM; PROCEDURES; PROTEIN PROCESSING; SIZE EXCLUSION CHROMATOGRAPHY;

BIOTECHNOLOGY; CELL MEMBRANE; CELLS, CULTURED; CHROMATOGRAPHY, GEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE EXPRESSION; GLYCOSYLATION; HEK293 CELLS; HUMANS; MASS SPECTROMETRY; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS;

EID: 84939960876     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-015-9857-2     Document Type: Erratum

References (61)

1. Welsh, M. J., Ramsey, B. W., Accurso, F., & Cutting, G. R. (2014). Cystic Fibrosis. In A. L. Beaudet, B. Vogelstein, K. W. Kinzler, S. E. Antonarakis, A. Ballabio, K. M. Gibson, & G. Mitchell (Eds.), The online metabolic and molecular bases of inherited disease. New York: The McGraw-Hill Companies Inc.
2. Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science,245, 1066–1073.
3. Sheppard, D. N., & Welsh, M. J. (1999). Structure and function of the CFTR chloride channel. Physiological Reviews,79, S23–S45.
4. Lukacs, G. L., Mohamed, A., Kartner, N., Chang, X. B., Riordan, J. R., & Grinstein, S. (1994). Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO Journal,13, 6076–6086.
5. Chong, P. A., Kota, P., Dokholyan, N. V., & Forman-Kay, J. D. (2013). Dynamics intrinsic to cystic fibrosis transmembrane conductance regulator function and stability. Cold Spring Harbor Perspectives in Medicine,3, a009522.
6. Pranke, I. M., & Sermet-Gaudelus, I. (2014). Biosynthesis of cystic fibrosis transmembrane conductance regulator. International Journal of Biochemistry & Cell Biology,52C, 26–38.
7. Riordan, J. R. (2008). CFTR function and prospects for therapy. Annual Review of Biochemistry,77, 701–726.
8. Prince, L. S., Workman, R. B, Jr, & Marchase, R. B. (1994). Rapid endocytosis of the cystic fibrosis transmembrane conductance regulator chloride channel. Proceedings of the National Academy of Sciences of the United States of America,91, 5192–5196.
9. Farinha, C. M., Matos, P., & Amaral, M. D. (2013). Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi. FEBS Journal,280, 4396–4406.
10. Gadsby, D. C., Vergani, P., & Csanady, L. (2006). The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature,440, 477–483.
11. Moran, O. (2014). On the structural organization of the intracellular domains of CFTR. International Journal of Biochemistry & Cell Biology,52C, 7–14.
12. Hegedus, T., Aleksandrov, A., Mengos, A., Cui, L., Jensen, T. J., & Riordan, J. R. (2009). Role of individual R domain phosphorylation sites in CFTR regulation by protein kinase A. Biochimica et Biophysica Acta,1788, 1341–1349.
13. Cant, N., Pollock, N., & Ford, R. C. (2014). CFTR structure and cystic fibrosis. International Journal of Biochemistry & Cell Biology,52, 15–25.
14. Dawson, J. E., Farber, P. J., & Forman-Kay, J. D. (2013). Allosteric coupling between the intracellular coupling helix 4 and regulatory sites of the first nucleotide-binding domain of CFTR. PLoS ONE,8, e74347.
15. Hunt, J. F., Wang, C., & Ford, R. C. (2013). Cystic fibrosis transmembrane conductance regulator (ABCC7) structure. Cold Spring Harbor Perspectives in Medicine,3, a009514.
16. Serohijos, A. W., Hegedus, T., Aleksandrov, A. A., He, L., Cui, L., Dokholyan, N. V., & Riordan, J. R. (2008). Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proceedings of the National Academy of Sciences of the United States of America,105, 3256–3261.
17. Rowe, S. M., & Verkman, A. S. (2013). Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harbor Perspectives in Medicine,3, a009746.
18. Galietta, L. J. (2013). Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors. Paediatric Drugs,15, 393–402.
19. Hanrahan, J. W., Sampson, H. M., & Thomas, D. Y. (2013). Novel pharmacological strategies to treat cystic fibrosis. Trends in Pharmacological Sciences,34, 119–125.
20. Lukacs, G. L., & Verkman, A. S. (2012). CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends in Molecular Medicine,18, 81–91.
21. Ikpa, P. T., Bijvelds, M. J., & de Jonge, H. R. (2014). Cystic fibrosis: Toward personalized therapies. International Journal of Biochemistry & Cell Biology,52, 192–200.
22. Chen, W., Wu, X., Levasseur, D. N., Liu, H., Lai, L., Kappes, J. C., & Townes, T. M. (2000). Lentiviral vector transduction of hematopoietic stem cells that mediate long-term reconstitution of lethally irradiated mice. Stem Cells,18, 352–359.
23. Kawate, T., & Gouaux, E. (2006). Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure,14, 673–681.
24. Naldini, L., Blomer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proceedings of the National Academy of Sciences of the United States of America,93, 11382–11388.
25. Zacharias, D. A., Violin, J. D., Newton, A. C., & Tsien, R. Y. (2002). Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. Science,296, 913–916.
26. Zufferey, R., Donello, J. E., Trono, D., & Hope, T. J. (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. Journal of Virology,73, 2886–2892.
27. Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. Journal of Virology,72, 9873–9880.
28. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnology,15, 871–875.
29. McClure, M., DeLucas, L. J., Wilson, L., Ray, M., Rowe, S. M., Wu, X., et al. (2012). Purification of CFTR for mass spectrometry analysis: identification of palmitoylation and other post-translational modifications. Protein Engineering, Design & Selection,25, 7–14.
30. de Felipe, P., Luke, G. A., Hughes, L. E., Gani, D., Halpin, C., & Ryan, M. D. (2006). E unum pluribus: Multiple proteins from a self-processing polyprotein. Trends in Biotechnology,24, 68–75.
31. Donnelly, M. L., Hughes, L. E., Luke, G., Mendoza, H., ten Dam, E., Gani, D., & Ryan, M. D. (2001). The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. Journal of General Virology,82, 1027–1041.
32. Donnelly, M. L., Luke, G., Mehrotra, A., Li, X., Hughes, L. E., Gani, D., & Ryan, M. D. (2001). Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: A putative ribosomal ‘skip’. Journal of General Virology,82, 1013–1025.
33. Howard, M., DuVall, M. D., Devor, D. C., Dong, J. Y., Henze, K., & Frizzell, R. A. (1995). Epitope tagging permits cell surface detection of functional CFTR. American Journal of Physiology,269, C1565–C1576.
34. Schultz, B. D., Takahashi, A., Liu, C., Frizzell, R. A., & Howard, M. (1997). FLAG epitope positioned in an external loop preserves normal biophysical properties of CFTR. American Journal of Physiology,273, C2080–C2089.
35. Mohanty, A. K., Simmons, C. R., & Wiener, M. C. (2003). Inhibition of tobacco etch virus protease activity by detergents. Protein Expression and Purification,27, 109–114.
36. Liu, L., Spurrier, J., Butt, T. R., & Strickler, J. E. (2008). Enhanced protein expression in the baculovirus/insect cell system using engineered SUMO fusions. Protein Expression and Purification,62, 21–28.
37. Panavas, T., Sanders, C., & Butt, T. R. (2009). SUMO fusion technology for enhanced protein production in prokaryotic and eukaryotic expression systems. Methods in Molecular Biology,497, 303–317.
38. Atwell, S., Brouillette, C. G., Conners, K., Emtage, S., Gheyi, T., Guggino, W. B., et al. (2010). Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. Protein Engineering, Design & Selection,23, 375–384.
39. Peroutka, R. J., Elshourbagy, N., Piech, T., & Butt, T. R. (2008). Enhanced protein expression in mammalian cells using engineered SUMO fusions: Secreted phospholipase A2. Protein Science,17, 1586–1595.
40. Muller, S., Hoege, C., Pyrowolakis, G., & Jentsch, S. (2001). SUMO, ubiquitin’s mysterious cousin. Nature Reviews Molecular Cell Biology,2, 202–210.
41. Zhang, S., Blount, A. C., McNicholas, C. M., Skinner, D. F., Chestnut, M., Kappes, J. C., et al. (2013). Resveratrol enhances airway surface liquid depth in sinonasal epithelium by increasing CFTR channel open probability. PLoS ONE,8(11), e81589.
42. Urlinger, S., Baron, U., Thellmann, M., Hasan, M. T., Bujard, H., & Hillen, W. (2000). Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proceedings of the National Academy of Sciences of the United States of America,97, 7963–7968.
43. Wu, X., Wakefield, J. K., Liu, H., Xiao, H., Kralovics, R., Prchal, J. T., & Kappes, J. C. (2000). Development of a novel trans-lentiviral vector that affords predictable safety. Molecular Therapy,2, 47–55.
44. Mulky, A., Sarafianos, S. G., Arnold, E., Wu, X., & Kappes, J. C. (2004). Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo. Journal of Virology,78, 7089–7096.
45. Ren, H. Y., Grove, D. E., De La Rosa, O., Houck, S. A., Sopha, P., Van Goor, F., et al. (2013). VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Molecular Biology of the Cell,24, 3016–3024.
46. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature,227, 680–685.
47. Naren, A. P. (2002). Methods for the study of intermolecular and intramolecular interactions regulating CFTR function. Methods in Molecular Medicine,70, 175–186.
48. Aleksandrov, A. A., Cui, L., & Riordan, J. R. (2009). Relationship between nucleotide binding and ion channel gating in cystic fibrosis transmembrane conductance regulator. The Journal of physiology,587, 2875–2886.
49. Cui, L., Aleksandrov, L., Hou, Y. X., Gentzsch, M., Chen, J. H., Riordan, J. R., & Aleksandrov, A. A. (2006). The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating. The Journal of physiology,572, 347–358.
50. Bajrami, B., Ramos, A., Diego, P., Coutermarsh, B. A., Stanton, B. A., Joseloff, E., & Yao, X. (2011). High-throughput and accurate quantitation of cell surface CFTR using stable isotopes and mass spectrometry: A potential tool to assist with CF drug discovery. Pediatric Pulmonology,27, 221–223.
51. Jiang, H., Ramos, A. A., & Yao, X. (2010). Targeted quantitation of overexpressed and endogenous cystic fibrosis transmembrane conductance regulator using multiple reaction monitoring tandem mass spectrometry and oxygen stable isotope dilution. Analytical Chemistry,82, 336–342.
52. Drew, D., Lerch, M., Kunji, E., Slotboom, D. J., & de Gier, J. W. (2006). Optimization of membrane protein overexpression and purification using GFP fusions. Nature Methods,3, 303–313.
53. Chang, X. B., Mengos, A., Hou, Y. X., Cui, L., Jensen, T. J., Aleksandrov, A., et al. (2008). Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator. Journal of Cell Science,121, 2814–2823.
54. Howard, M., Jiang, X., Stolz, D. B., Hill, W. G., Johnson, J. A., Watkins, S. C., et al. (2000). Forskolin-induced apical membrane insertion of virally expressed, epitope-tagged CFTR in polarized MDCK cells. American Journal of Physiology. Cell Physiology,279, C375–C382.
55. Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., et al. (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell,63, 827–834.
56. Aleksandrov, A. A., & Riordan, J. R. (1998). Regulation of CFTR ion channel gating by MgATP. FEBS Letters,431, 97–101.
57. Rosenberg, M. F., Kamis, A. B., Aleksandrov, L. A., Ford, R. C., & Riordan, J. R. (2004). Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR). Journal of Biological Chemistry,279, 39051–39057.
58. Zhang, L., Aleksandrov, L. A., Zhao, Z., Birtley, J. R., Riordan, J. R., & Ford, R. C. (2009). Architecture of the cystic fibrosis transmembrane conductance regulator protein and structural changes associated with phosphorylation and nucleotide binding. Journal of Structural Biology,167, 242–251.
59. Hildebrandt, E., Zhang, Q., Cant, N., Ding, H., Dai, Q., Peng, L., et al. (2014). A survey of detergents for the purification of stable, active human cystic Fibrosis transmembrane conductance regulator (CFTR). Biochimica et Biophysica Acta (BBA): Biomembranes,70, 414–417.
60. Baron, U., & Bujard, H. (2000). Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods in Enzymology,327, 401–421.
61. Pluta, K., Luce, M. J., Bao, L., Agha-Mohammadi, S., & Reiser, J. (2005). Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. Journal of Gene Medicine,7, 803–817.